Execution of a grant agreement with The Michael J. Fox Foundation for the NEK7 project

Current report no. 39/2026

Date: 29 September 2026

Subject: Execution of a grant agreement with The Michael J. Fox Foundation for the NEK7 project

Legal Basis: Article 17(1) MAR – inside information

Content of the Report:

The Management Board of Captor Therapeutics S.A. (the "Company", "Captor") hereby announces that on 29 September 2026, the Company executed a grant agreement with The Michael J. Fox Foundation for Parkinson’s Research ("MJFF").

Under the terms of the agreement, Captor will receive non-dilutive grant funding in the amount of USD 2,000,000 (two million US dollars) to support the further advancement and development of its brain-penetrant NEK7 project in neurodegenerative diseases.

Key Terms of the Grant Agreement

• Funding Amount: USD 2,000,000.
• Scope of Research: The grant will fund advanced research and development activities for Captor's targeted protein degradation candidates directed against NEK7—a key regulator of the NLRP3 inflammasome implicated in neuroinflammation and neurodegenerative disorders, including Parkinson's disease.
• Intellectual Property: Captor retains full ownership of all intellectual property rights related to the project and any technology developed under the grant.

Significance of the Agreement

Securing this grant provides Captor with significant non-dilutive financial resources dedicated to expanding its differentiated pipeline. In addition, partnering with MJFF - a premier global leader in Parkinson's disease research - provides scientific validation of Captor’s target selection and proprietary targeted protein degradation platform.